Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson

Completed · Early Phase 1

Conditions studied: Ischemic Heart Disease

In brief

This is a pilot study to determine whether the drug regadenoson can be used during magnetic resonance imaging to assess regions of poor blood flow to the heart. The hypothesis of this study is that a single injection of regadenoson could be used instead of a standard adenosine infusion to produce coronary vasodilatation and demonstrate myocardial ischemia during first-pass perfusion cardiac MRI.

Key facts

Study ID

NCT00881218

Run by

Washington University School of Medicine

People needed

50

Starts

2009-06-01

Expected to finish

2011-12-01

Last updated by the study team

2012-04-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• reversible perfusion abnormalities on a clinically ordered rest/adenosine dual-isotope SPECT-MPI in at least 2 contiguous myocardial segments (per 17-segment model)

You may not qualify if…

• myocardial infarction, myocardial revascularization procedure or progression in angina occuring after the SPECT-MPI examination
• pregnancy
• gadolinium-based MR contrast allergy
• glomerular filtration rate (GFR) > 60 mL/min/1.73 m2
• contraindications to MR imaging (pacemaker, brain aneurysm clips, schrapnel, etc.)

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.